Trial Shows Micardis(R) (telmisartan) Reduces The Risk Of Cardiovascular Death, Heart Attack And Stroke In ACE-Intolerant High-Risk Patients Part 4

C-reactive protein, a dial of inflammation, be considered an emerging stake factor contained via settle on of cardiovascular illness (CVD), according to the American Heart Association.1 Studies of CRP hold demonstrated that impenetrable height be associated near a higher risk for growing coronary trial.2 The specific uniformity linking contraction in CRP and reduction of CVD risk have not be verified and no drugs are official freeway for use up and going on for in reducing CRP.

The title holder of the ONTARGET® Trial Programme is Boehringer Ingelheim; co-funders in selected country be Bayer HealthCare and GlaxoSmithKline.

Boehringer Ingelheim The Boehringer Ingelheim working group is one of the world's 20 primary pharmaceutical firm. Headquartered in Ingelheim, Germany, it operate universal with 135 affiliate in 47 countries and 39,800 workforce. Since it be found in 1885, the family-owned company own be committed to research, embryonic, engineering and marketing radical products of great counteractive utility in favour of human and veterinary pills.

In 2007, Boehringer Ingelheim post trellis sale of 10.9 billion euro while overheads one fifth of net sales in its largest conglomerate segment Prescription Medicines nearby research and perfection.

Related links: Boehringer Ingelheim pinch pack - European Society of Cardiology Congress 2008 (ESC)Ontarget-Telmisartan website (for Healthcare Professionals masquerade the U.S. only)Micardis® website (for Healthcare Professionals outside the U.S. only) References: 1. The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular contact in high-risk patients unmoved to angiotensin-converting enzyme inhibitors: a randomized controlled testing. Lancet Published online 31 August 2008.

2.The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-53.

3. The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high stake for vascular events. N Eng J Med 2008; 358(15):1547-59.

4. Israili ZH, Hall WD. Cough and angioedema associated with angiotensin-coverting enzyme inhibitor psychiatric aid. A reassessment of the literature and pathophysiology. Ann Intern Med 1992; 117(3):234-42.

5.Matchar DB, et al. Systematic Review: Comparative efficiency of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treat indispensable hypertension.

Ann Intern Med 2008; 148:16-29.

6. Macaulay TE, Dunn SP. Cross-reactivity of ACE-inhibitor-induced angioedema with ARBs. US Pharmacist 2007; 32 (2).

7. World Health Organization, Fact Sheet 317: Cardiovascular Diseases February 2007. (Accessed August 2008) 8. Murray CJL, Lopez AD. eds. The Global Burden of Disease: A privileged rough calculation of mortality and disability from disease, hurt, and risk factor in 1990 and projected to 2020.

Cambridge; Harvard University Press 2001.

9. Primary Prevention of Ischemic Stroke. A Guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37:1583-1633.

Boehringer Ingelheim

Read more about pharmacy